Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)

NCT02452047 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Bacterial Infections

Interventions

DRUG: Imipenem+Cilastatin/Relebactam
DRUG: Colistimethate sodium (CMS)
DRUG: Imipenem+Cilastatin
DRUG: Placebo to CMS

Sponsor

Merck Sharp & Dohme LLC